Ligand Pharmaceuticals LGND Other — Total revenues and income
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other — total revenues and income.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other — total revenues and income?
- Ligand Pharmaceuticals (LGND) reported other — total revenues and income of $3.76M in Q1 2026.
- How has Ligand Pharmaceuticals's other — total revenues and income changed year-over-year?
- Ligand Pharmaceuticals's other — total revenues and income increased by 2.5% year-over-year, from $3.67M to $3.76M.
- What does other — total revenues and income mean?
- This metric represents the aggregate financial inflows derived from royalty-based intangible assets and miscellaneous secondary business activities within the 'Other' segment. It captures revenue streams that fall outside of primary core operations, reflecting the monetization of intellectual property and ancillary service agreements. Monitoring this helps investors assess the contribution of non-core assets to the company's overall financial performance.